Financial News

Crispr Therapeutics’ stock soars as FDA-panel meeting raises hopes sickle-cell-disease drug will be approved

Crispr Therapeutics' stock rallied 12% Wednesday amid hopes a treatment for sickle-cell disease will win regulatory approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback